 MELBOURNE, Australia and KING OF PRUSSIA, Pa., Oct. 18, 2021 PRNewswire -- During its annual RD investment briefing earlier today, CSL Limited ASX:CSL; USOTC:CSLLY highlighted progress from its novel pipeline that spans six therapeutic areas immunology, hematology, respiratory, cardiovascular and metabolic, transplant, influenza, four scientific platforms plasma fractionation, recombinant technology, cell and gene therapy, vaccines and two businesses CSL Behring and Seqirus. 